Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway

被引:17
作者
Nyga, Mari [1 ,11 ]
Engesaeter, Birgit [1 ]
Castle, Philip E. [2 ,3 ]
Berland, Jannicke Mohr [4 ]
Eide, Maj Liv [5 ]
Iversen, Ole Erik [6 ,7 ]
Jonassen, Christine Monceyron [8 ]
Christiansen, Irene Kraus [9 ]
Vintermyr, Olav Karsten [7 ,10 ]
Trope, Ameli [1 ]
机构
[1] Canc Registry Norway, Oslo, Norway
[2] NCI, Div Canc Prevent, NIH, Rockville, MD USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[4] Stavanger Univ Hosp, Stavanger, Rogaland, Norway
[5] Trondheim Reg & Univ Hosp, Trondheim, Norway
[6] Univ Bergen, Inst Clin Sci, Bergen, Norway
[7] Haukeland Hosp, Bergen, Norway
[8] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway
[9] Akershus Univ Hosp, Lorenskog, Norway
[10] Univ Bergen, Gades Lab Pathol, Bergen, Norway
[11] Canc Reg istry Norway, Res Dept, Postbox Majorstuen 5313, N-0304 Oslo, Norway
关键词
INTRAEPITHELIAL NEOPLASIA; FOLLOW-UP; CYTOLOGY; RISK; PREVENTION; TRIAGE;
D O I
10.1158/1055-9965.EPI-22-0340
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). For safe technol-ogy transfer within the nationwide screening programme in Nor-way, HPV-Screening protocol was implemented randomized to compare the real-world effectiveness of HPV-Screening protocol and LBC-Screening protocol at the first screening round. Methods: Among 302,295 women ages 34 to 69 years scheduled to attend screening from February 2015 to June 2017, 157,447 attended. A total of 77,207 were randomly allocated to the HPV-Screening protocol and 80,240 were allocated to the LBC-Screening protocol. All women were followed up for 18 months. Results: The HPV-Screening protocol resulted in a relative increase of 60% in the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse [risk ratio (RR) = 1.6, 95% confidence interval (CI) = 1.5-1.7], 40% in CIN grade 3 or worse (RR = 1.4, 95% CI = 1.3-1.6), 40% in cancer (RR = 1.4, 95% CI = 1.0-2.1), and 60% in colposcopy referrals (RR = 1.6, 95% CI = 1.5-1.6) compared with LBC-Screening. The perfor-mance of both protocols was age dependent, being more effective in women ages under 50 years. Conclusions: The HPV-Screening protocol was well accepted by women in Norway and detected more CIN2, CIN3, and cancers compared with the LBC-Screening protocol.Impact: A randomized implementation of the HPV-Screening protocol with real-world assessment enabled a gradual, quality assured, and safe technology transition. HPV-based screening protocol may further be improved by using HPV genotyping and age-specific referral algorithms.
引用
收藏
页码:1812 / 1822
页数:11
相关论文
共 40 条
[1]   Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study [J].
Aitken, Clare A. ;
van Agt, Heleen M. E. ;
Siebers, Albert G. ;
van Kemenade, Folkert J. ;
Niesters, Hubert G. M. ;
Melchers, Willem J. G. ;
Vedder, Judith E. M. ;
Schuurman, Rob ;
van den Brule, Adriaan J. C. ;
van der Linden, Hans C. ;
Hinrichs, John W. J. ;
Molijn, Anco ;
Hoogduin, Klaas J. ;
van Hemel, Bettien M. ;
de Kok, Inge M. C. M. .
BMC MEDICINE, 2019, 17 (01)
[2]   Attendance to cervical cancer screening among Roma and non-Roma women living in North-Western region of Romania [J].
Andreassen, Trude ;
Melnic, Adriana ;
Figueiredo, Rejane ;
Moen, Kare ;
Suteu, Ofelia ;
Nicula, Florian ;
Ursin, Giske ;
Weiderpass, Elisabete .
INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2018, 63 (05) :609-619
[3]  
Anttila A., 2015, EUROPEAN GUIDELINES
[4]   2020 list of human papillomavirus assays suitable for primary cervical cancer screening [J].
Arbyn, Marc ;
Simon, Marie ;
Peeters, Eliana ;
Xu, Lan ;
Meijer, Chris J. L. M. ;
Berkhof, Johannes ;
Cuschieri, Kate ;
Bonde, Jesper ;
Vanlencak, Anja Ostrbenk ;
Zhao, Fang-Hui ;
Rezhake, Remila ;
Gultekin, Murat ;
Dillner, Joakim ;
de Sanjose, Silvia ;
Canfell, Karen ;
Hillemanns, Peter ;
Almonte, Maribel ;
Wentzensen, Nicolas ;
Poljak, Mario .
CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (08) :1083-1095
[5]   Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer [J].
Arbyn, Marc ;
Ronco, Guglielmo ;
Anttila, Ahti ;
Meijer, Chris J. L. M. ;
Poljak, Mario ;
Ogilvie, Gina ;
Koliopoulos, George ;
Naucler, Pontus ;
Sankaranarayanan, Rengaswamy ;
Peto, Julian .
VACCINE, 2012, 30 :F88-F99
[6]   Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway [J].
Burger, E. A. ;
Ortendahl, J. D. ;
Sy, S. ;
Kristiansen, I. S. ;
Kim, J. J. .
BRITISH JOURNAL OF CANCER, 2012, 106 (09) :1571-1578
[7]  
Darum A, 2015, VEILEDER GYNEKOLOGIS
[8]   Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study [J].
Dillner, Joalim ;
Rebolj, Matejka ;
Birembaut, Philippe ;
Petry, Karl-Ulrich ;
Szarewski, Anne ;
Munk, Christian ;
de Sanjose, Silvia ;
Naucler, Pontus ;
Lloveras, Belen ;
Kjaer, Susanne ;
Cuzick, Jack ;
van Ballegooijen, Marjolein ;
Clavel, Christine ;
Iftner, Thomas .
BRITISH MEDICAL JOURNAL, 2008, 337 (7676) :a1754
[9]   Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study [J].
Engesaeter, Birgit ;
Hidle, Bianca van Diermen ;
Hansen, Mona ;
Moltu, Pia ;
Staby, Kjersti Mangseth ;
Borchgrevink-Persen, Siri ;
Vintermyr, Olav K. ;
Lonnberg, Stefan ;
Nygard, Mari ;
Janssen, Emiel A. M. ;
Castle, Philip E. ;
Christiansen, Irene Kraus .
BMC INFECTIOUS DISEASES, 2016, 16
[10]  
Finnish Cancer Registry, RAND HLTH SERV STUD